bluebird bio, Inc.

How big is bluebird bio, Inc.?

As of Jun 03, bluebird bio, Inc. has a market capitalization of 48.41 million and reported net sales of 103.94 million with a net profit of -199.98 million over the latest four quarters. Shareholder's funds are at -31.53 million, and total assets amount to 460.23 million.

As of Jun 03, bluebird bio, Inc. has a market capitalization of 48.41 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 03, the sum of net sales for the latest four quarters is 103.94 million, while the sum of net profit for the same period is -199.98 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at -31.53 million, and total assets amount to 460.23 million.

What does bluebird bio, Inc. do?

bluebird bio, Inc. is a clinical-stage biotechnology company focused on gene therapies for severe diseases and cancer, with a market cap of $48.41 million and recent net sales of $39 million. The company reported a net loss of $29 million in its latest quarterly results.

Overview:<BR>bluebird bio, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for severe diseases and cancer, operating within the micro-cap market.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 39 Million (Quarterly Results - Mar 2025)<BR>- Most recent Net Profit: -29 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 48.41 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 2,008.21%<BR>- Debt Equity: -1.22<BR>- Return on Equity: 335.69%<BR>- Price to Book: -0.84<BR><BR>Contact Details:<BR>- Address: 60 Binney St, CAMBRIDGE MA: 02142-1512<BR>- Tel: ['1 339 4999300', '1 410 9605022']<BR>- Fax: 1 302 6365454<BR>- Website: http://www.bluebirdbio.com

Should I buy, sell or hold bluebird bio, Inc.?

Who are in the management team of bluebird bio, Inc.?

As of March 2022, the management team of bluebird bio, Inc. includes Daniel Lynch (Independent Chairman), Nick Leschly (CEO), Ramy Ibrahim, Denice Torres, John Agwunobi, Wendy Dixon, and David Schenkein (all Independent Directors). They oversee the company's strategic direction and operations.

As of March 2022, the management team of bluebird bio, Inc. includes the following individuals:<BR><BR>- Mr. Daniel Lynch, Independent Chairman of the Board<BR>- Mr. Nick Leschly, President, Chief Executive Officer, Director<BR>- Mr. Ramy Ibrahim, Director<BR>- Ms. Denice Torres, Director<BR>- Dr. John Agwunobi, Independent Director<BR>- Dr. Wendy Dixon, Independent Director<BR>- Dr. David Schenkein, Independent Director<BR><BR>This team is responsible for overseeing the company's strategic direction and operations.

Is bluebird bio, Inc. technically bullish or bearish?

As of May 12, 2025, bluebird bio, Inc. shows a mildly bearish trend with mixed technical indicators, significantly underperforming the S&P 500 with a year-to-date return of -40.41% compared to 12.22%.

As of 12 May 2025, the technical trend for bluebird bio, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish overall, with key indicators including a mildly bullish MACD on both weekly and monthly time frames, and a bullish RSI on the monthly. However, the daily moving averages are mildly bearish, and Bollinger Bands indicate a bearish trend on the weekly and mildly bearish on the monthly. <BR><BR>In terms of returns, bluebird bio has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -40.41% compared to the S&P 500's 12.22%, and a one-year return of -72.25% versus 17.14%.